Pathology: Osteoarthritis (OA) Pain Therapeutics

• Publication date: November 2011

GlobalData, the market analysis specialist, has released its new report, “”. The report is an essential source of information and analysis on the global Osteoarthritis pain Therapeutics industry . The report identifies the major industry developments shaping and driving the global Osteoarthritis pain Therapeutics industry . The report also provides insights on the prevalent competitive landscape and the emerging players expected to s...

GlobalData, the market analysis specialist, has released its new report, “”. The report is an essential source of information and analysis on the global Osteoarthritis pain Therapeutics industry . The report identifies the major industry developments shaping and driving the global Osteoarthritis pain Therapeutics industry . The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the industry positioning of the current industry leaders. Most importantly, the report provides valuable insights on the new product development within the global Osteoarthritis pain Therapeutics segment . This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Industry expert's team of market experts.

Scope of the Research

- The report provides data on the key drivers and challenges of the Osteoarthritis pain Therapeutics industry . Its Scope of the Research includes:
- Annualized seven key industry s (US, France, Germany, Italy, Spain, UK and Japan) Osteoarthritis pain Therapeutics industry revenues data 2005-2009, projection for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key industry s. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Osteoarthritis pain Therapeutics industry .
- Insightful review of the key market drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, industry characterization, unmet needs and the implications for the Osteoarthritis pain Therapeutics therapeutics industry .
- Analysis of key recent licensing and partnership agreements in Osteoarthritis pain Therapeutics industry

Why Should You Get This Report?

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of new product development and technologies and by identifying the industry players with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Osteoarthritis pain Therapeutics industry .
- Drive revenues by understanding the major industry developments, innovative products and technologies, industry sectors and industry players likely to impact the global Osteoarthritis pain Therapeutics industry in future.
- Formulate effective sales and industry ing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and industry ing efforts by identifying the industry categories and sectors that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Osteoarthritis pain Therapeutics industry landscape? – Identify, understand and decide.

Therapy Industry in Japan

1 Table of contents

I Table of contents 2
I. 1 List of Data tables 4
I. 2 List of Charts 5

II OA Pain Therapeutics: Introduction 6
II. 1 Disease Data 6
II. 1.1 OA Pain 9
II. 2 Epidemiology 9
II. 3 Etiology and Pathophysiology 9
II. 3.1 Evolution of the Disease 10
II. 4 Signs and Symptoms 12
II. 5 Diagnosis 13
II. 5.1 Commonly Used Diagnosis Tests 13
II. 6 Treatment and Management Options 14
II. 7 GlobalData Pipeline Report Guidance 15

III OA PainTherapeutics: March ket Characterization 16
III. 1 OA Pain Therapeutics March ket Size (2005-2010) – World 16
III. 2 OA Pain Therapeutics March ket Forecasted data (2010-2017) – World 17
III. 3 OA Pain Therapeutics March ket Size (2005-2010) – The US 18
III. 4 OA Pain Therapeutics March ket Forecasted data (2010-2017) – The US 19
III. 5 OA Pain Therapeutics March ket Size (2005-2010) – France 20
III. 6 OA Pain Therapeutics March ket Forecasted data (2010-2017) – France 21
III. 7 OA Pain Therapeutics March ket Size (2005-2010) – Germany 22
III. 8 OA Pain Therapeutics March ket Forecasted data (2010-2017) – Germany 23
III. 9 OA Pain Therapeutics March ket Size (2005-2010) – Italy 24
III. 10 OA Pain Therapeutics March ket Forecasted data (2010-2017) – Italy 25
III. 11 OA Pain Therapeutics March ket Size (2005-2010) – Spain 26
III. 12 OA Pain Therapeutics March ket Forecasted data (2010-2017) – Spain 27
III. 13 OA Pain Therapeutics March ket Size (2005-2010) – The UK 28
III. 14 OA Pain Therapeutics March ket Forecasted data (2010-2017) – The UK 29
III. 15 OA Pain Therapeutics March ket Size (2005-2010) – Japan 30
III. 16 OA Pain Therapeutics March ket Forecasted data (2010-2017) – Japan 31
III. 17 Drivers and Barriers for the OA Pain Therapeutics March ket 32
III. 17.1 Drivers for the OA Pain Therapeutics March ket 32
III. 17.2 Barriers for the OA Pain Therapeutics March ket 33
III. 18 Opportunity and Unmet Need Analysis 33
III. 19 Key Takeaway 34

IV OA Pain Therapeutics: Competitive Assessment 35
IV. 1 Overview 35
IV. 1.1 Strategic Competitor Assessment 35
IV. 2 Product Profiles for the Major March keted Products in the OA Pain Therapeutics March ket 36
IV. 2.1 Celebrex (celecoxib) 36
IV. 2.2 Voltaren Gel (diclofenac sodium) 37
IV. 2.3 Morphine 37
IV. 2.4 Hyalgan (sodium hyaluronate) 39
IV. 3 Key Takeaway 39

V OA Pain Therapeutics: Pipeline Assessment 40
V. 1 Overview 40
V. 2 Strategic Pipeline Assessment 40
V. 3 OA Pain Therapeutics Pipeline – Pipeline by Phases of Development 40
V. 3.1 OA Pain Therapeutics – Regulatory Filed Products 41
V. 3.2 OA Pain Therapeutics – Phase III Pipeline 41
V. 3.3 OA Pain Therapeutics – Phase II Pipeline 42
V. 3.4 OA Pain Therapeutics – Phase I Pipeline 42
V. 3.5 OA Pain March ket – Discovery and Pre-Clinical Pipeline 43
V. 3.6 Technology Trends Analytic Framework 43
V. 4 OA Pain Therapeutics March ket – Clinical Pipeline by Mechanism of Action 45
V. 5 OA Pain Therapeutics – Promising Drugs Under Clinical Development 46
V. 6 Molecule Profile for Promising Drugs Under Clinical Development 46
V. 6.1 2PX 46
V. 6.2 Nucynta ER (tapentadol) 47
V. 7 Key Takeaway 48

VI OA Pain Therapeutics: Clinical Trials Mapping 49
VI. 1 Clinical Trials by Region/Country (the US, EU5 and Japan) 49
VI. 2 Clinical Trials by Phase 50
VI. 3 Clinical Trials by Trial Status 51
VI. 4 Key Sponsors 52
VI. 5 Top Firms Participating in OA Pain Therapeutics Clinical Trials 54

VII Strategic Assessment 55
VII. 1 Key Events Impacting the Future March ket 55
VII. 2 OA Pain Therapeutics: Implications for Future March ket Competition 56

VIII OA Pain Therapeutics: Future Players 57
VIII. 1 Introduction 57
VIII. 2 Firms Profiles 57
VIII. 2.1 Abbott laboratories 57
VIII. 2.2 Adolor Corporation 62
VIII. 2.3 Cephalon, Inc. 63
VIII. 2.4 Endo Pharmaceuticals 65
VIII. 2.5 Elite Pharmaceuticals 67
VIII. 2.6 Glenmark Pharmaceuticals 69
VIII. 2.7 Grunenthal GmbH 71
VIII. 2.8 Johnson & Johnson Pharmaceutical Research & development, L.L.C. 74
VIII. 2.9 Pfizer, Inc. 75
VIII. 2.10 Sanofi-Aventis 79
VIII. 2.11 Other Firms in the OA Pain Therapeutics March ket 82

IX OA Pain Therapeutics: Licensing and Partnership Deals 83

X OA Pain Therapeutics: Appendix 84
X. 1 March ket Definitions 84
X. 2 Abbreviations 84
X. 3 Research Methodology 85
X. 3.1 Coverage 85
X. 3.2 Secondary Research 85
X. 3.3 Forecasted data ing 86
X. 3.4 Primary Research 88
X. 3.5 Expert Panel Validation 89
X. 4 Contact Us 89
X. 5 Disclaimer 89
X. 6 Bibliography 89

List of Tables

Data table 1: OA Pain Therapeutics March ket, Global, Sales ($bn), 2005–2010 16
Data table 2: OA Pain Therapeutics March ket, Global, Forecasted data ($bn), 2010–2017 17
Data table 3: OA Pain Therapeutics March ket, The US, Sales ($bn), 2005–2010 18
Data table 4: OA Pain Therapeutics March ket, The US, Forecasted data s ($bn), 2010–2017 19
Data table 5: OA Pain Therapeutics March ket, France, Sales (USD Million), 2005–2010 20
Data table 6: OA Pain Therapeutics March ket, France, Forecasted data s (USD Million), 2010–2017 21
Data table 7: OA Pain Therapeutics March ket, Germany, Sales (USD Million), 2005–2010 22
Data table 8: OA Pain Therapeutics March ket, Germany, Forecasted data s (USD Million), 2010–2017 23
Data table 9: OA Pain Therapeutics March ket, Italy, Sales (USD Million), 2005–2010 24
Data table 10: OA Pain Therapeutics March ket, Italy, Forecasted data s (USD Million), 2010–2017 25
Data table 11: OA Pain Therapeutics March ket, Spain, Sales (USD Million), 2005–2010 26
Data table 12: OA Pain Therapeutics March ket, Spain, Forecasted data s (USD Million), 2010–2017 27
Data table 13: OA Pain Therapeutics March ket, The UK, Sales (USD Million), 2005–2010 28
Data table 14: OA Pain Therapeutics March ket, The UK, Forecasted data s (USD Million), 2010–2017 29
Data table 15: OA Pain Therapeutics March ket, Japan, Sales (USD Million), 2005–2010 30
Data table 16: OA Pain Therapeutics March ket, Japan, Forecasted data s (USD Million), 2010–2017 31
Data table 17: OA Pain Therapeutics – Regulatory Filed Products, 2010 41
Data table 18: OA Pain Therapeutics – Phase III Pipeline, 2010 41
Data table 19: OA Pain Therapeutics – Phase II Pipeline, 2010 42
Data table 20: OA Pain Therapeutics – Phase I Pipeline, 2010 42
Data table 21: OA Pain Therapeutics – Discovery and Pre-Clinical Pipeline, 2010 43
Data table 22: OA Pain Therapeutics – Most Promising Drugs Under Clinical Development, 2010 46
Data table 23: OA Pain Therapeutics – Clinical Trials by Country, 2010 49
Data table 24: OA Pain Therapeutics – Clinical Trials by Phase, 2011 50
Data table 25: OA Pain Therapeutics – Clinical Trials by Status, 2011 51
Data table 26: OA Pain Therapeutics, Overall Sponsors 52
Data table 27: OA Pain Therapeutics, Most Key Sponsors 53
Data table 28: OA Pain Therapeutics - Top Firms Participating in Therapeutics Clinical Trials, 2010 54
Data table 29: Acura Pharmaceuticals – Pain Management, Pipeline, 2010 60
Data table 30: Abbott Laboratories – Deals, from 2009 to 2011 61
Data table 31: OA Pain Therapeutics, Adolor Corporation, Pain Management Pipeline 2010 63
Data table 32: Adolor Corporation, Deals, from 2009 to 2011 63
Data table 33: OA Pain Therapeutics, Cephalon, Inc., OA Pain Therapeutics Pipeline, 2010 65
Data table 34: Cephalon, Inc., Deals, from 2009 to 2011 65
Data table 35: Endo Pharmaceuticals, Pain Management Therapeutic Pipeline, 2010 66
Data table 36: Endo Pharmaceuticals, Deals, from 2009 to 2011 67
Data table 37: OA Pain Therapeutics, Elite Pharmaceuticals Pain Management Pipeline, 2010 68
Data table 38: OA Pain Therapeutics, Elite Pharmaceuticals OA Pain Pipeline, 2010 68
Data table 39: Elite Pharmaceuticals, Deals, from 2009 to 2011 69
Data table 40: Glenmark Pharmaceuticals, OA Pain Pipeline, 2010 70
Data table 41: Glenmark Pharmaceuticals, Deals, from 2009 to 2011 71
Data table 42: Grunenthal GMBH, Pain Management Pipeline, 2010 72
Data table 43: Grunenthal GmbH – Deals, from 2009 to 2011 73
Data table 44: Johnson & Johnson Pharmaceutical R&D L.L.C., OA Pain Management Pipeline, 2010 75
Data table 45: J&JPRD, Deals, from 2009 to 2011 75
Data table 46: Pfizer, Pain Management Pipeline, 2010 77
Data table 47: Pfizer, OA Pain Pipeline, 2010 78
Data table 48: Pfizer, Inc., Deals, from 2009 to 2011 78
Data table 49: OA Pain Therapeutics, Sanofi-aventis Pain Management Pipeline, 2010 80
Data table 50: Sanofi-aventis, Deals, from 2009 to 2011 81
Data table 51: OA Pain Therapeutics March ket – Future Players 82
Data table 52: Licensing and Partnership Deals, from 2008 to 2011 83

List of Figures

Chart 1: Osteoarthritis of the Knee 6
Chart 2: Osteoarthritis of the Knee 7
Chart 3: Osteoarthritis of the Hand, Heberden’s Nodes 7
Chart 4: Osteoarthritis of the Hand, Bouchard’s Nodes 8
Chart 5: Osteoarthritis of the Hip 8
Chart 6: OA Pain Pathophysiology 10
Chart 7: OA Pain Pathophysiology 10
Chart 8: OA Pain Pathophysiology 11
Chart 9: OA Pain Pathophysiology 11
Chart 10: OA Pain Pathophysiology 12
Chart 11: OA Pain, Treatment Pattern 15
Chart 12: OA Pain Therapeutics March ket, Global, Sales ($bn), 2005–2010 16
Chart 13: OA Pain Therapeutics March ket, Global, Forecasted data ($bn), 2010–2017 17
Chart 14: OA Pain Therapeutics March ket, The US, Sales ($bn), 2005–2010 18
Chart 15: OA Pain Therapeutics March ket, The US, Forecasted data ($bn), 2010–2017 19
Chart 16: OA Pain Therapeutics March ket, France, Sales (USD Million), 2005–2010 20
Chart 17: OA Pain Therapeutics March ket, France, Forecasted data (USD Million), 2010–2017 21
Chart 18: OA Pain Therapeutics March ket, Germany, Sales (USD Million), 2005–2010 22
Chart 19: OA Pain Therapeutics March ket, Germany, Forecasted data (USD Million), 2010–2017 23
Chart 20: OA Pain Therapeutics March ket, Italy, Sales (USD Million), 2005–2010 24
Chart 21: OA Pain Therapeutics March ket, Italy, Forecasted data (USD Million), 2010–2017 25
Chart 22: OA Pain Therapeutics March ket, Spain, Sales (USD Million), 2005–2010 26
Chart 23: OA Pain Therapeutics March ket, Spain, Forecasted data (USD Million), 2010–2017 27
Chart 24: OA Pain Therapeutics March ket, The UK, Sales (USD Million), 2005–2010 28
Chart 25: OA Pain Therapeutics March ket, The UK, Forecasted data (USD Million), 2010–2017 29
Chart 26: OA Pain Therapeutics March ket, Japan, Sales (USD Million), 2005–2010 30
Chart 27: OA Pain Therapeutics March ket, Japan, Forecasted data (USD Million), 2010–2017 31
Chart 28: Opportunity and Unmet Need in the OA Pain Therapeutics March ket 34
Chart 29: OA Pain Therapeutics – Strategic Competitor Assessment, 2010 35
Chart 30: OA Pain Therapeutics – Pipeline by Phase of Development, 2010 40
Chart 31: OA Pain Therapeutics – Technology Trends Analytics Framework, 2010 44
Chart 32: OA Pain Therapeutics – Technology Trends Analytics Framework – Description, 2010 44
Chart 33: OA Pain Therapeutics – Pipeline by Mechanism of Action, 2010 45
Chart 34: OA Pain Therapeutics – Clinical Trials by Country, 2010 49
Chart 35: OA Pain Therapeutics – Clinical Trials by Phase, 2011 50
Chart 36: OA Pain Therapeutics – Clinical Trials by Status, 2011 51
Chart 37: OA Pain Therapeutics – Overall Sponsors, 2011 52
Chart 38: OA Pain Therapeutics – Key Sponsors, 2010 53
Chart 39: OA Pain Therapeutics – Top Firms Participating in Therapeutics Clinical Trials, 2010 54
Chart 40: OA Pain Therapeutics March ket, Drivers and Barriers 2010 55
Chart 41: Implications for Future March ket Competition in the OA Pain March ket, 2010 56
Chart 42: OA Pain Therapeutics March ket – Pipeline by Firms, 2010 57
Chart 43: GlobalData March ket Forecasted data ing Model 88

Companies Mentioned
Abbott laboratories
Adolor Corporation
Cephalon, Inc.
Endo Pharmaceuticals
Elite Pharmaceuticals
Glenmark Pharmaceuticals
Grunenthal GmbH
Johnson & Johnson Pharmaceutical Research & development, L.L.C.
Pfizer, Inc.
Sanofi-Aventis